Healthcare provider profile · identity verified

Peter J. Kim, MD

Family Practice · ANAHEIM, CA · NPI 1194897678

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	929	296
Amlodipine Besylate	Amlodipine Besylate	583	186
Rosuvastatin Calcium	Rosuvastatin Calcium	402	134
Lisinopril	Lisinopril	393	121
Losartan Potassium	Losartan Potassium	341	108
Simvastatin	Simvastatin	295	94
Levothyroxine Sodium	Levothyroxine Sodium	274	81
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	246	84
Metformin Hcl Er	Metformin Hcl	242	83
Atenolol	Atenolol	240	68
Ozempic	Semaglutide	233	41
Jardiance	Empagliflozin	203	65
Alendronate Sodium	Alendronate Sodium	200	76
Omeprazole	Omeprazole	198	80
Tamsulosin Hcl	Tamsulosin Hcl	180	65
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	178	37
Metformin Hcl	Metformin Hcl	142	36
Metoprolol Tartrate	Metoprolol Tartrate	137	39
Ezetimibe	Ezetimibe	131	46
Trazodone Hcl	Trazodone Hcl	109	29
Hydrochlorothiazide	Hydrochlorothiazide	107	34
Pradaxa	Dabigatran Etexilate Mesylate	107	33
Potassium Chloride	Potassium Chloride	95	40
Terazosin Hcl	Terazosin Hcl	95	25
Albuterol Sulfate Hfa	Albuterol Sulfate	92	44
Pantoprazole Sodium	Pantoprazole Sodium	85	30
Triamcinolone Acetonide	Triamcinolone Acetonide	76	49
Meloxicam	Meloxicam	72	24
Allopurinol	Allopurinol	71	22
Gabapentin	Gabapentin	71	27
Glipizide	Glipizide	68	24
Spironolactone	Spironolactone	60	18
Finasteride	Finasteride	59	19
Fluoxetine Hcl	Fluoxetine Hcl	55	18
Nifedipine Er	Nifedipine	53	15
Tramadol Hcl	Tramadol Hcl	53	suppressed
Clopidogrel	Clopidogrel Bisulfate	51	17
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	51	50
Sertraline Hcl	Sertraline Hcl	51	19
Pravastatin Sodium	Pravastatin Sodium	48	16
Bisoprolol Fumarate	Bisoprolol Fumarate	47	16
Montelukast Sodium	Montelukast Sodium	42	13
Alvesco	Ciclesonide	40	18
Carvedilol	Carvedilol	40	12
Ondansetron Odt	Ondansetron	38	12
Acyclovir	Acyclovir	37	18
Hydrocortisone	Hydrocortisone	35	13
Pioglitazone Hcl	Pioglitazone Hcl	35	14
Azelastine Hcl	Azelastine Hcl	34	suppressed
Furosemide	Furosemide	34	13
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	31	31
Chlorthalidone	Chlorthalidone	31	12
Humulin N	Insulin Nph Human Isophane	31	12
Wixela Inhub	Fluticasone Propion/Salmeterol	30	14
Venlafaxine Hcl Er	Venlafaxine Hcl	29	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	28	suppressed
Propranolol Hcl	Propranolol Hcl	27	11
Duloxetine Hcl	Duloxetine Hcl	26	11
Hydralazine Hcl	Hydralazine Hcl	26	11
Lorazepam	Lorazepam	26	11
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	26	11
Warfarin Sodium	Warfarin Sodium	26	12
Glipizide Er	Glipizide	25	12
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	25	suppressed
Cephalexin	Cephalexin	24	20
Twinrix	Hepatitis A And B Vaccine/Pf	24	16
Donepezil Hcl	Donepezil Hcl	23	suppressed
Naproxen	Naproxen	23	suppressed
Victoza 2-Pak	Liraglutide	23	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	22	20
Spiriva Respimat	Tiotropium Bromide	22	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	21	suppressed
Ibuprofen	Ibuprofen	21	suppressed
Nitroglycerin	Nitroglycerin	21	15
Testosterone	Testosterone	21	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	20	20
Humulin N Kwikpen	Insulin Nph Human Isophane	20	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	20	suppressed
Baclofen	Baclofen	19	suppressed
Eliquis	Apixaban	19	suppressed
Estradiol	Estradiol	19	suppressed
Fluticasone Propionate	Fluticasone Propionate	19	suppressed
Ipratropium Bromide	Ipratropium Bromide	19	suppressed
Alprazolam	Alprazolam	18	suppressed
Amoxicillin	Amoxicillin	18	16
Liraglutide	Liraglutide	17	suppressed
Prednisone	Prednisone	17	14
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Metronidazole	Metronidazole	16	suppressed
Xarelto	Rivaroxaban	16	suppressed
Bupropion Xl	Bupropion Hcl	15	suppressed
Fluocinonide	Fluocinonide	15	suppressed
Azithromycin	Azithromycin	14	13
Citalopram Hbr	Citalopram Hydrobromide	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	14	suppressed
Famotidine	Famotidine	14	suppressed
Humulin R	Insulin Regular, Human	14	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	14	suppressed
Mupirocin	Mupirocin	14	11
Fentanyl	Fentanyl	13	suppressed
Mirtazapine	Mirtazapine	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Ibandronate Sodium	Ibandronate Sodium	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Butalb-Acetaminoph-Caff-Codein	Butalbit/Acetamin/Caff/Codeine	11	suppressed
Colchicine	Colchicine	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	11	suppressed
Repatha Sureclick	Evolocumab	11	suppressed
Temazepam	Temazepam	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error